<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288664</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGLN-002</org_study_id>
    <nct_id>NCT01288664</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release
      Capsules (ADVAGRAF) for the induction therapy of Lupus Nephritis (LN) (V, III +V, IV+V).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    sponsor withdraw from this study
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete or partial remission)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proteinuria</measure>
    <time_frame>every 3 months,up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores</measure>
    <time_frame>every 3 months, up to 6 months</time_frame>
    <description>SLEDAI (Systemic Lupus Erythematosus Disease Activity Index, Bombardier et al, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>every 3 months, up to 6 months</time_frame>
    <description>Adverse events,including infections, transient increases in serum creatinine, gastrointestinal complaints, liver function disorder and glucose intolerance, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>every 3 months, up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>every 3 months, up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVAGRAF</intervention_name>
    <description>Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.</description>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <other_name>ADVAGRAF:Tacrolimus Sustained-release Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex, 14-65 years of age;

          2. Diagnosis of systemic lupus erythematosus (SLE) according to the albumin-creatinine
             ratio (ACR) criteria (1997);

          3. Kidney biopsy within the 6 months prior to study with a histologic diagnosis (ISN/RPS
             2003 classification of LN) class V, III +V, IV+V;

          4. LN (Class IV+V): proteinuria &gt; 1g/24hr or Scr &gt; 1.3 mg/dl or active urinary sediment
             (erythrocyte cast, &gt; 5 white blood cell count (WBC) /high power field (hpf)(excluding
             infection ), &gt; 5 red blood cell count (RBC)/hpf;

          5. LN (Class V or III +V ): proteinuria &gt; 2g/24hr or Scr &gt; 1.3 mg/dl;

          6. Provision of written informed consent by subject or guardian

        Exclusion Criteria:

          1. Inability or unwillingness to provide written informed consent

          2. Usage of immunosuppression therapy (MMF, Cyclophosphamide (CTX), Cyclosporine A
             (CysA), methotrexate (MTX) ect) for more than 1 week within 1 month or Pulse
             intravenous MP treatment prior to recruitment

          3. Scr &gt; 4mg/dl (354umol/L)

          4. Needing pulse intravenous Methylprednisolone (MP) or intravenous immunoglobulin

          5. Lupus encephalopathy

          6. Diagnosed diabetes mellitus (DM); Malignant tumors (except fully cured basal cell
             carcinoma)

          7. History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or
             active peptic ulcer disease) within 3 month prior to enter this study

          8. Any Active systemic infection or history of serious infection within one month of
             entry

          9. known infection with HIV, hepatitis B, or hepatitis C

         10. Known hypersensitivity or contraindication to tacrolimus, corticosteroids

         11. Participation in another clinic trial and/or receipt of investigational drugs within 4
             weeks prior to screening

         12. Pregnancy, nursing or use of a non-reliable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Xueqing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Xueqing Yu</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Lupus Nephritis</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Induction Phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

